Gene delivery to mitotic and postmitotic photoreceptors Via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The purpose of the present study was to test the therapeutic efficiency and safety of compacted‐DNA nanoparticle‐mediated gene delivery into the subretinal space of a juvenile mouse model of retinitis pigmentosa. Nanoparticles containing the mouse opsin promoter and wild‐type mouse Rds gene were injected subretinally into mice carrying a haploinsufficiency mutation in the retinal degeneration slow ( rds +/− ) gene at postnatal day (P)5 and 22. Control mice were either injected with saline, injected with uncompacted naked plasmid DNA carrying the Rds gene, or remained untreated. Rds mRNA levels peaked at postinjection day 2 to 7 (PI‐2 to PI‐7) for P5 injections, stabilized at levels 2‐fold higher than in uninjected controls for both P5 and P22 injections, and remained elevated at the latest time point examined (PI‐120). Rod function (measured by electroretinography) showed modest but statistically significant improvement compared with controls after both P5 and P22 injections. Cone function in nanoparticle‐injected eyes reached wild‐type levels for both ages of injections, indicating full prevention of cone degeneration. Ultrastructural examination at PI‐120 revealed significant improvement in outer segment structures in P5 nanoparticle‐injected eyes, while P22 injection had a modest structural improvement. There was no evidence of macrophage activation or induction of IL‐6 or TNF‐α mRNA in P5 or P22 nanoparticle‐dosed eyes at either PI‐2 or PI‐30. Thus, compacted‐DNA nanoparticles can efficiently and safely drive gene expression in both mitotic and postmitotic photoreceptors and retard degeneration in this model. These findings, using a clinically relevant treatment paradigm, illustrate the potential for application of nanoparticle‐based gene replacement therapy for treatment of human retinal degenerations.—Cai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., Naash, M. I. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 24, 1178–1191 (2010). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208 · cited 4×
“We have recently characterized transgene expression profiles after delivery of these nanoparticles to the WT eye (20).”
BackgroundMethodInfluentialSelf-citationBainbridge, J., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A., & Ali, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301574 · Cited by 197 · cited 1×
“There have been several studies (27, 28, 38, 46, 47) reporting large differences in transfection or transduction efficiency depending on the age of treatment.”
BackgroundFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“These nanoparticles can deliver a wide range of cargo sizes and have been effectively utilized with plasmids as big as 20 kb (24).”
BackgroundSelf-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 1×
“As confirmation, saline-injected eyes were also examined by immunohistochemistry, and no mAB 3B6 immunostaining was detected (37).”
BackgroundSelf-citation
Cited by
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.04.015 · Cited by 433
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Nanotechnology in Ocular Drug Delivery
Patel, D., Pathak, D., & Giradkar, P. (2021) · Nanocarriers: Drug Delivery System · doi:10.1007/978-981-33-4497-6_18 · Cited by 362
Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo
Xu, Q., Boylan, N. J., Suk, J. S., Wang, Y.-Y., Nance, E. A., Yang, J.-C., McDonnell, P. J., Cone, R. A., Duh, E. J., & Hanes, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.018 · Cited by 326
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150
Self-citationGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Self-citationNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Self-citationKoirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75
Self-citationGene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
Self-citationLi, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-0134-z · Cited by 68
Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype
Han, Z., Banworth, M. J., Makkia, R., Conley, S. M., Al‐Ubaidi, M. R., Cooper, M. J., & Naash, M. I. (2015) · The FASEB Journal · doi:10.1096/fj.15-270363 · Cited by 54
“Subretinal injections were performed at postnatal day 3, as previously described (21).”
BackgroundMethodSelf-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Self-citationOcular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Koirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47
Self-citation
Metadata
- Authors
- Cai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., & Naash, M. I.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2009-10
- Volume
- 24
- Issue
- 4
- Pages
- 1178-1191
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2164992413
- Cited by
- 120
- References
- 4
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.